Obesity-linked Liver Cancer Preventable, but Rising
That's a key message from a new Lancet Commission report on addressing the global hepatocellular carcinoma (HCC) burden, published online on July 28 to coincide with World Hepatitis Day.
The burden of new liver cancer cases is projected to increase to 1.52 million, and liver cancer-related deaths are projected to increase to 1.37 million by 2050, the commission pointed out.
In addition, the share of liver cancer cases caused by metabolic dysfunction-associated steatohepatitis (MASH), a severe form of MASLD, is expected to increase by 35% (8%-11%) by 2050.
The commission called for increased public, medical, and political awareness of the rising risk for MASLD — especially in the US, Europe, and Asia — with a focus on high-risk groups, such as those with diabetes and/or obesity.
With the number of new liver cancer cases predicted to double over the next 25 years without urgent action, the Commission set a target for an annual reduction of 2%-5% in the number of new cases. This could prevent up to 17 million liver cancer cases and up to 15 million deaths, if achieved.
10 Recommendations
Overall, the commission suggested 10 strategies for reducing the global burden of liver cancer and improving patients' quality of life. These include:
1. Strengthening viral hepatitis prevention, screening, and treatment, including integrating hepatitis B virus vaccination into national immunization schedules and targeted hepatitis C virus (HCV) screening.
2. Reducing alcohol consumption using 'strong government-led measures,' such as warning labels and advertisement restrictions.
3. Controlling environmental risk factors, especially exposure to contaminated water and aflatoxins in food in low- and middle-income countries.
4. Preparing for the increase in MASLD and MASH with tailored national strategies for awareness, screening, and management.
5. Raising awareness of liver health among policy makers and the general population.
6. Improving early HCC detection by optimizing the performance of surveillance tests and technologies.
7. Standardizing noninvasive diagnoses of HCC with standardized criteria for interpreting imaging studies.
8. Addressing East-West differences in clinical management through collaborative efforts of professional organizations and the pharmaceutical industry to achieve consensus and a clear action plan.
9. Improving HCC survivorship through research, clinical documentation of outcomes, complications and treatment response, and integration of palliative care in the early phases for patients in need.
10. Facilitating access to treatment for HCV and HCC, which currently is limited mainly due to high cost and lack of cost-effectiveness.
Zeroing in on Obesity
The rate of MASLD-linked liver cancer is expected to rise over the next decade, particularly in the US, Europe, and Asia, due to increasing rates of obesity, the report authors warned.
In the US, MASLD prevalence continues to climb in parallel with the obesity epidemic; by 2040, over 55% of US adults could have MASLD, the commission predicted.
'Liver cancer was once thought to occur mainly in patients with viral hepatitis or alcohol-related liver disease,' commission author Hashem B El-Serag, MD, Baylor College of Medicine, Houston, commented in a press release. 'However, today rising rates of obesity are an increasing risk factor for liver cancer, primarily due to the increase in cases of excess fat around the liver.'
El-Serag suggested including screening for liver damage into routine healthcare practice for patients at high risk for MASLD, such as individuals living with obesity, diabetes, and cardiovascular disease. 'Healthcare professionals should also integrate lifestyle counselling into routine care to support patients to transition to a healthy diet and regular physical activity,' he said. 'Furthermore, policy makers must promote healthy food environments via policies such as sugar taxes and clear labelling on products with high fat, salt, and/or sugar.'
In a related editorial, The Lancet editorial board concluded, 'The message of the Commission — that strengthening prevention, fostering collaboration, and removing social and knowledge barriers can help avert the rapid rise of liver cancer — is one of possibility. Taking action to realize that possibility is vital for the health of many millions of people worldwide over the next 25 years.'
The Commission was supported by grants from the Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, and Shanghai Municipal Science and Technology Major Project. A list of authors with competing interests is available in the report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Why Moderna (MRNA) Stock Is Trading Lower Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Moderna? Access our full analysis report here, it's free. What Is The Market Telling Us Moderna's shares are extremely volatile and have had 53 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 4.9% on the news that industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an 'unprecedented medical cost trend environment,' particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well. Moderna is down 34.6% since the beginning of the year, and at $27.47 per share, it is trading 70.8% below its 52-week high of $94.17 from July 2024. Investors who bought $1,000 worth of Moderna's shares 5 years ago would now be looking at an investment worth $352.27. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. 登入存取你的投資組合
Fast Company
2 hours ago
- Fast Company
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022. The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision. But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid. Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal. Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal. 'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added. Moderna did not immediately respond to a request for comment. Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic. The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
